Shah, Gunjan L.
Boelens, Jaap Jan
Carlow, Dean
Lin, Andrew
Schofield, Ryan
Cruz Sitner, Nancy
Alperovich, Anna
Ruiz, Josel
Proli, Anthony
Dahi, Parastoo
Tamari, Roni
Giralt, Sergio A.
Scordo, Michael
Admiraal, Rick http://orcid.org/0000-0003-1512-2791
Funding for this research was provided by:
national institutes of health (P01 CA23766)
division of cancer epidemiology and genetics, national cancer institute (P30 CA008748)
Article History
Accepted: 9 November 2021
First Online: 2 December 2021
Declarations
:
: The study was supported by funding from the Sawiris Family Research Fund, Melvin Berlin Family Fund for Myeloma Research, A.C. Israel Foundation, and the Donna and Patrick Martin Foundation. This research was supported in part by National Institutes of Health award number P01 CA23766 and National Institutes of Health/National Cancer Institute Cancer Center Support grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The work was performed independently of all funders.
: GS reports research funding from Janssen and Amgen unrelated to the current project. MS has served as a consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; has received research funding from Angiocrine Bioscience, Inc. and Omeros Corporation; has served on an advisory board for Kite, a Gilead Company; and has served as a CME speaker for i3Health, all unrelated to the current project. JB has received honoraria for consulting for Race Oncology, AvroBio, Omeros, Sanofi, Advanced Clinical, and BlueRock, all unrelated to the current project. SG has consulted for and received research funding from Amgen, Actinium, Celgene, Johnson & Johnson, and Takeda; has consulted for Jazz Pharmaceuticals, Novartis, Kite, and Spectrum Pharmaceuticals; and has received research funding from Miltenyi unrelated to the current project. MS has received research support from Angiocrine Bioscience, Inc. and Omeros Corporation; has consulted for Angiocrine Bioscience, Inc., Omeros Corporation and McKinsey & Company; has advised for Kite , a Gilead Company; and received a speaking engagement from i3Health. RA has received research grants from Sanofi, unrelated to the current project.
: Not applicable.
: Not applicable.
: Not applicable.
: The data and materials for this study are not available.
: The model codes are available upon request.
: RA and GS designed and conducted the research, analyzed the data, and wrote the paper; DC and RS analyzed the samples and wrote the paper; JJB, SG, and MS initiated the research and wrote the paper; AL, NCS, AA, JR, AP, PD, and RT wrote the paper.